Profile data is unavailable for this security.
About the company
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
- Revenue in USD (TTM)17.00k
- Net income in USD-23.47m
- Incorporated2015
- Employees23.00
- LocationvTv Therapeutics Inc3980 Premier Dr, Suite 310HIGH POINT 27265United StatesUSA
- Phone+1 (336) 841-0300
- Fax+1 (336) 841-0310
- Websitehttps://vtvtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Black Diamond Therapeutics Inc | 70.00m | 21.50m | 126.48m | 24.00 | 6.12 | 1.00 | 5.79 | 1.81 | 0.3629 | 0.3629 | 1.23 | 2.22 | 0.4736 | -- | -- | 2,916,667.00 | 14.54 | -42.24 | 16.58 | -46.05 | -- | -- | 30.71 | -- | -- | -- | 0.00 | -- | -- | -- | 15.48 | -- | -- | -- |
| AVITA Medical Inc | 72.40m | -48.56m | 127.43m | 260.00 | -- | -- | -- | 1.76 | -1.81 | -1.81 | 2.70 | -0.2186 | 1.00 | 1.63 | 7.50 | 278,461.50 | -67.07 | -- | -147.57 | -- | 84.81 | -- | -67.06 | -- | 0.5519 | -8.20 | 1.19 | -- | 28.14 | -- | -74.80 | -- | -- | -- |
| Oramed Pharmaceuticals, Inc. | 2.00m | 43.85m | 129.36m | 13.00 | 3.23 | 0.6529 | 2.94 | 64.68 | 1.01 | 1.01 | 0.0478 | 4.98 | 0.0104 | -- | -- | 153,846.20 | 22.72 | -- | 23.30 | -- | 0.65 | -- | 2,190.40 | -- | -- | -- | 0.00 | -- | -100.00 | -- | -444.98 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -67.51m | 132.70m | 28.00 | -- | 1.03 | -- | -- | -5.51 | -5.51 | 0.00 | 7.35 | 0.00 | -- | -- | 0.00 | -49.34 | -69.78 | -55.11 | -97.84 | -- | -- | -- | -5,894.85 | -- | -- | 0.00 | -- | -- | -- | 9.85 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -33.47m | 133.25m | 22.00 | -- | 3.45 | -- | -- | -2.85 | -2.85 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -74.93 | -188.44 | -101.88 | -723.53 | -- | -- | -- | -6,003.20 | -- | -- | 0.00 | -- | -100.00 | -- | -20.42 | -- | -- | -- |
| vTv Therapeutics Inc | 17.00k | -23.47m | 133.39m | 23.00 | -- | 1.89 | -- | 7,846.40 | -3.32 | -3.32 | 0.0024 | 17.91 | 0.0002 | -- | -- | 739.13 | -39.79 | -96.30 | -46.08 | -- | -- | -- | -166,935.30 | -775.06 | -- | -- | 0.0046 | -- | -- | -18.12 | 8.83 | -- | -- | -- |
| Spero Therapeutics Inc | 40.55m | -43.84m | 134.65m | 32.00 | -- | 5.08 | -- | 3.32 | -0.7949 | -0.7949 | 0.7299 | 0.4705 | 0.4283 | -- | 1.45 | 1,267,156.00 | -46.31 | -35.16 | -69.26 | -42.63 | -- | -- | -108.11 | -111.75 | -- | -- | 0.00 | -- | -53.77 | 21.46 | -400.65 | -- | -- | -- |
| Vaxart Inc | 148.20m | -50.70m | 135.88m | 105.00 | -- | 4.84 | -- | 0.9168 | -0.2222 | -0.2222 | 0.6495 | 0.1169 | 0.789 | -- | 3.31 | 1,411,467.00 | -26.99 | -49.90 | -80.48 | -58.33 | -- | -- | -34.21 | -875.06 | -- | -31.43 | 0.1161 | -- | 288.94 | 23.82 | 18.82 | -- | -8.21 | -- |
| Sangamo Therapeutics Inc | 32.88m | -108.91m | 138.20m | 183.00 | -- | 19.96 | -- | 4.20 | -0.4428 | -0.4428 | 0.1326 | 0.0194 | 0.3289 | -- | 5.97 | 179,644.80 | -108.96 | -30.73 | -204.29 | -37.33 | -- | -- | -331.28 | -147.59 | -- | -- | 0.00 | -- | -67.20 | -10.81 | 62.01 | -- | -58.10 | -- |
| HST Global Inc | 0.00 | -212.63k | 139.70m | 1.00 | -- | 8.48 | -- | -- | -0.0107 | -0.0107 | 0.00 | 0.1167 | 0.00 | -- | -- | -- | -6.87 | -27.80 | -8.09 | -60.19 | -- | -- | -- | -- | -- | -107.48 | 0.0433 | -- | -- | -- | -45.42 | -- | -- | -- |
| Nkarta Inc | 0.00 | -102.61m | 139.93m | 105.00 | -- | 0.4141 | -- | -- | -1.39 | -1.39 | 0.00 | 4.76 | 0.00 | -- | -- | 0.00 | -21.39 | -29.78 | -22.36 | -31.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.41 | -- | 17.99 | -- |
| Prelude Therapeutics Inc | 10.50m | -111.77m | 140.19m | 131.00 | -- | 2.16 | -- | 13.35 | -1.47 | -1.47 | 0.1382 | 1.03 | 0.0719 | -- | -- | 80,152.67 | -76.56 | -47.36 | -88.86 | -51.44 | -- | -- | -1,064.50 | -7,615.23 | -- | -- | 0.00 | -- | -- | -- | -4.38 | -- | -0.4137 | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 141.07m | 97.00 | -- | 1.30 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| Fate Therapeutics Inc | 7.14m | -156.09m | 144.19m | 181.00 | -- | 0.616 | -- | 20.20 | -1.32 | -1.32 | 0.0603 | 2.03 | 0.017 | -- | 2.30 | 39,430.94 | -37.23 | -32.44 | -40.38 | -36.57 | -- | -- | -2,187.11 | -389.06 | -- | -- | 0.00 | -- | -78.55 | 5.00 | -15.74 | -- | -37.07 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -58.01m | 144.79m | 33.00 | -- | 7.06 | -- | -- | -0.8938 | -0.8938 | 0.00 | 0.2407 | 0.00 | -- | -- | 0.00 | -68.07 | -48.63 | -75.01 | -52.10 | -- | -- | -- | -1,201.96 | -- | -73.28 | 0.7327 | -- | -100.00 | -- | 30.44 | -- | -39.67 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 762.00k | -50.77m | 145.35m | 62.00 | -- | 2.62 | -- | 190.75 | -0.9144 | -0.9144 | 0.0137 | 0.9926 | -- | -- | -- | 12,290.32 | -- | -61.12 | -- | -66.78 | -- | -- | -6,662.99 | -1,963.00 | -- | -- | 0.00 | -- | -- | -- | 74.84 | -- | 37.04 | -- |
Data as of Feb 13 2026. Currency figures normalised to vTv Therapeutics Inc's reporting currency: US Dollar USD
21.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Trails Edge Capital Partners LPas of 29 Aug 2025 | 231.00k | 5.87% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 192.89k | 4.90% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 148.31k | 3.77% |
| Invus Public Equities Advisors LLCas of 30 Sep 2025 | 143.44k | 3.64% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 66.00k | 1.68% |
| Geode Capital Management LLCas of 31 Dec 2025 | 28.19k | 0.72% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 16.13k | 0.41% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 14.07k | 0.36% |
| Millennium Management LLCas of 30 Sep 2025 | 12.94k | 0.33% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 10.30k | 0.26% |
More ▼
Data from 30 Sep 2025 - 03 Feb 2026Source: FactSet Research Systems Inc.
